KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

BioNTech SE's Cash & Equivalents history spans 8 years, with the latest figure at $11.7 billion for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 12.63% to $11.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.7 billion, a 12.63% increase, with the full-year FY2025 number at $11.4 billion, up 9.31% from a year prior.
  • Cash & Equivalents hit $11.7 billion in Q4 2025 for BioNTech SE, roughly flat from $11.8 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for BNTX hit a ceiling of $1459786.9 billion in Q1 2021 and a floor of $1.4 billion in Q3 2021.
  • Historically, Cash & Equivalents has averaged $73093.7 billion across 5 years, with a median of $12.2 billion in 2023.
  • The widest YoY moves for Cash & Equivalents: up 631.05% in 2022, down 99.87% in 2022.
  • Tracing BNTX's Cash & Equivalents over 5 years: stood at $1.9 billion in 2021, then skyrocketed by 631.05% to $14.2 billion in 2022, then decreased by 11.35% to $12.5 billion in 2023, then dropped by 16.88% to $10.4 billion in 2024, then increased by 12.63% to $11.7 billion in 2025.
  • Business Quant data shows Cash & Equivalents for BNTX at $11.7 billion in Q4 2025, $11.8 billion in Q3 2025, and $11.5 billion in Q2 2025.